Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia

Bone Marrow Transplantation volume 26, pages 711–716 (2000)Cite this article

Abstract

To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etoposide in combination with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). The stem cell source was allogeneic related bone marrow (BM) (n = 53), allogeneic unrelated BM (n = 5), allogeneic unrelated peripheral blood (PBSC) (n = 2), syngeneic BM (n = 2), autologous BM purged (n = 9) or unpurged (n = 9), autologous PBSC (n = 10). fifty-six patients (62%) were in first cr, 26 (29%) were > first CR, and eight (9%) were transplanted in relapse. Principal toxicities in both groups were mucositis and hepatotoxicity. Forty-five mg/kg etoposide resulted in greater hepatic toxicity (P = 0.03), and a higher incidence of VOD (23 vs 12%, P = 0.04) and acute GVHD grade III/IV (13 vs 5%, NS). The treatment-related mortality was 17% in the 30 mg/kg group and 33% in the 45 mg/kg group, mainly due to infections, intestinal pneumonia and GVHD. Hematological recovery of leukocytes 1/nl was comparable in both groups (17 vs 16 days). After a median follow-up of 16 months 19% in the 30 mg/kg group and 23% in the 45 mg/kg group relapsed. In patients who had undergone allogeneic related bone marrow transplantation in first CR no relapses occurred after a median follow-up of 3 years. For all patients the 3-year estimated disease-free survival was 62% in the 30 mg/kg group and 40% in the 45 mg/kg group (P = 0.03). For patients in first CR who underwent allogeneic related stem cell transplantation the 3 year disease-free survivals were 80% and 66%, respectively (P = 0.4). We conclude that etoposide 30 mg/kg or 45 mg/kg in combination with busulfan/cyclophosphamide is a highly active regimen for bone marrow transplantation of patients with AML with a low relapse rate. However, conditioning with 30 mg/kg rather than 45 mg/kg etoposide resulted in less toxicity and a better overall survival due to a lower transplant-related mortality. Bone Marrow Transplantation (2000) 26, 711–716.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 2
Figure 1
Figure 3

Similar content being viewed by others

References

  1. Weinstein HJ, Mayer RJ, Rosenthal DS et al. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update Blood 1983 62: 315–319

    CAS  PubMed  Google Scholar 

  2. Cassileth PA, Lynch E, Hines JD et al. Varying intensity of postremission therapy in acute myeloid leukemia Blood 1992 79: 1924–1930

    CAS  PubMed  Google Scholar 

  3. Büchner T, Urbanitz D, Hiddemann W et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia J Clin Oncol 1985 3: 1583–1589

    PubMed  Google Scholar 

  4. Appelbaum FR . Allogeneic hematopoietic stem cell transplantation for acute leukemia Semin Oncol 1997 24: 114–123

    CAS  PubMed  Google Scholar 

  5. Linker CA, Ries CA, Damon LE et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen Blood 1993 81: 311–318

    CAS  PubMed  Google Scholar 

  6. Gorin NC, Najman A, Duhamel G . Autologous bone marrow transplantation in acute myeloid leukemia Lancet 1977 1: 1050

    CAS  PubMed  Google Scholar 

  7. Tutschka PJ, Copelan EA, Klein JA et al. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen Blood 1987 70: 1382–1388

    CAS  PubMed  Google Scholar 

  8. Körbling M, Hunstein W, Fliedner TM et al. Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia Blood 1989 74: 1898–1904

    PubMed  Google Scholar 

  9. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens Blood 1990 76: 1867–1871

    CAS  PubMed  Google Scholar 

  10. Zander AR, Culbert S, Jagannath S et al. High-dose cyclophosphamide, BCNU, and VP-16 as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia Cancer 1987 59: 1083–1086

    CAS  PubMed  Google Scholar 

  11. Mathe G, Schwarzenberg L, Pouillart P et al. Two epidophyllotoxin derivates VM 26 and VP16–213 in the treatment of leukemias, hematosarcomas, and lymphomas Cancer 1974 34: 985–991

    CAS  PubMed  Google Scholar 

  12. Smith IE, Gerken ME, Clink HM, McElwain TJ . VP 16–213 in acute myelogenous leukemia Postgrad Med J 1976 52: 66–70

    CAS  PubMed  PubMed Central  Google Scholar 

  13. van Echo DA, Wiernik PH, Aisner J . High-dose VP 16–213 for treatment of patients with previously treated acute leukemia Cancer Clin Trials 1980 3: 325–328

    CAS  PubMed  Google Scholar 

  14. Henwood JN, Brodgen RN . Etoposide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer Drugs 1990 39: 438–490

    CAS  PubMed  Google Scholar 

  15. Stadtmauer EA, Casselith PA, Gale RP et al. Etoposide in leukemia, lymphoma and bone marrow transplantation Leuk Res 1989 13: 639–650

    CAS  PubMed  Google Scholar 

  16. Wolff SN, McKay CM, Hande KR et al. High-dose VP16–213 and autologous bone marrow transplantation for refractory malignancies—a phase I study J Clin Oncol 1983 1: 701–705

    CAS  PubMed  Google Scholar 

  17. Spitzer TR, Cottler-Fox M, Torrisi J et al. Escalating doses of etoposide with cyclophosphamide and fractionated TBI or busulfan conditioning for BMT Bone Marrow Transplant 1989 4: 559–565

    CAS  PubMed  Google Scholar 

  18. Crilley P, Topolsky D, Styler MJ et al. Extramedullary toxicity of a conditioning regimen containing busulfan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogeneic bone marrow transplantation Bone Marrow Transplant 1995 15: 361–365

    CAS  PubMed  Google Scholar 

  19. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft vs host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295–304

    CAS  PubMed  Google Scholar 

  20. Zander AR, Zabelina T, Kröger N et al. Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow Bone Marrow Transplant 1999 23: 889–893

    CAS  PubMed  Google Scholar 

  21. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568

    CAS  PubMed  Google Scholar 

  22. Kaplan E, Meier P . Non-parametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Google Scholar 

  23. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute non-lymphomic leukemia after treatment with busulfan and cyclophosphamide New Engl J Med 1983 309: 1347–1353

    CAS  PubMed  Google Scholar 

  24. Tutschka PJ, Copelan EA, Klein JA et al. Bone marrow transplantation for leukemia following new busulfan and cyclophosphamide regime Blood 1987 70: 1382–1388

    CAS  PubMed  Google Scholar 

  25. Blaise D, Maraninchi D, Michallet M et al. BuCy(120) vs TBI/Cy to prepare allo-BMT for CR1 AML: a follow-up of a study from GEGMO Bone Marrow Transplant 1999 23: (Suppl.1) 228

    Google Scholar 

  26. Ringden O, Labopin M, Tura S . A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia Br J Haematol 1996 93: 637–645

    CAS  PubMed  Google Scholar 

  27. Hartmann AR, Williams SF, Dillon JJ . Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis Bone Marrow Transplant 1998 22: 439–443

    Google Scholar 

  28. Blume KG, Forman SJ, O’Donnel MR et al. Total body irradiation and high-dose etoposide: a new preparative regimen for bone marrow transplantation in patients with advanced hematological malignancies Blood 1987 69: 1015–1020

    CAS  PubMed  Google Scholar 

  29. Schmitz N, Gassmann W, Rister M et al. Fractionated total body irradiation and high-dose VP 16–213 followed by allogeneic bone marrow transplantation in advanced leukemias Blood 1988 72: 1567–1573

    CAS  PubMed  Google Scholar 

  30. Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group Study Blood 1993 81: 2187–2193

    CAS  PubMed  Google Scholar 

  31. Vaughan WP, Dennison JD, Reed EC et al. Improved results of allogenic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy Bone Marrow Transplant 1991 8: 489–495

    CAS  PubMed  Google Scholar 

  32. Chao NJ, Stein AS, Longo GD et al. Busulfan/etoposide-initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with AnLL Blood 1993 81: 319–323

    CAS  PubMed  Google Scholar 

  33. Spitzer TR, Cottler-Fox M, Torrisi J et al. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation Bone Marrow Transplant 1989 4: 559–565

    CAS  PubMed  Google Scholar 

  34. Zander AR, Berger C, Kröger N et al. High-dose chemotherapy with busulfan, cyclophosphamide and VP 16 as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission Clin Cancer Res 1997 3: 2671–2675

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the staff of the BMT unit for providing excellent care of our patients and the medical technicians for their excellent work in the BMT laboratory.

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany

    N Kröger, T Zabelina, S Sonnenberg, W Krüger, H Renges, N Stute, F Finkenstein, U Mayer, K Holstein, W Fiedler, R Erttmann, H Kabisch & AR Zander

  2. AK St Georg, Hamburg, Germany

    H Colberg, R Sonnen & R Kuse

  3. AK Altona, Hamburg, Germany

    D Braumann

  4. Städtische Kliniken, Oldenburg, Germany

    B Metzner & F del Valle

Authors
  1. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Zabelina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Sonnenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Krüger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Renges
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Stute
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Finkenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. U Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Holstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W Fiedler
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H Colberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R Sonnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R Kuse
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. D Braumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. B Metzner
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. F del Valle
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. R Erttmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. H Kabisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. AR Zander
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kröger, N., Zabelina, T., Sonnenberg, S. et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 26, 711–716 (2000). https://doi.org/10.1038/sj.bmt.1702598

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702598

Keywords

This article is cited by

Search

Advanced search

Quick links